A therapeutic target for smoking-associated lung cancer

Sci Transl Med. 2010 Dec 15;2(62):62ps56. doi: 10.1126/scitranslmed.3001942.

Abstract

A report in this issue of Science Translational Medicine reveals that amplification of the FGFR1 gene-which encodes fibroblast growth factor receptor 1-is a major oncogenic aberration in squamous cell lung cancer. This genetic variation may represent the first relatively high-frequency therapeutic target of smoking-associated lung cancer.

Publication types

  • Comment

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / metabolism
  • Adenocarcinoma of Lung
  • Animals
  • Apoptosis / genetics
  • Apoptosis / physiology
  • Blotting, Western
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Cell Line
  • Enzyme Inhibitors / therapeutic use
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / metabolism*
  • Male
  • Mice
  • Mice, Nude
  • Pyrimidines / therapeutic use
  • RNA Interference
  • Receptor, Fibroblast Growth Factor, Type 1 / antagonists & inhibitors
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics
  • Receptor, Fibroblast Growth Factor, Type 1 / metabolism*
  • Xenograft Model Antitumor Assays

Substances

  • Enzyme Inhibitors
  • PD 173074
  • Pyrimidines
  • Receptor, Fibroblast Growth Factor, Type 1